Samsrita Labs Ltd (539267)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 11 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 11 நவ. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Samsrita Labs Ltd reported Q2 FY27 results on 11 Nov 2026: revenue ₹0.0 Cr, and net profit ₹-0.3 Cr (a smaller loss than a year earlier).
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.0 | — | — |
| செயல்பாட்டு லாபம் | ₹-0.1 | நஷ்டம் குறைந்தது | நஷ்டம் குறைந்தது |
| நிகர லாபம் | ₹-0.3 | நஷ்டம் குறைந்தது | நஷ்டம் அதிகரித்தது |
| EPS (₹) | -0.12 | நஷ்டம் குறைந்தது | நஷ்டம் அதிகரித்தது |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Samsrita Labs Limited submitted its quarterly Statement of Deviation or Variation under Regulation 32 of SEBI LODR for the quarter ended September 30, 2026. The company confirmed zero deviation in the utilization of proceeds raised via a preferential issue dated July 18, 2025, which totaled ₹339.10 lakh. Out of these proceeds, ₹52.10 lakh was originally allocated to working capital and has been utilized for the same object without modification. The Audit Committee reviewed and noted the statement on November 11, 2026.
- Total funds raised via preferential issue: ₹339.10 lakh
- Fund raising date: July 18, 2025
- Report filed for the quarter ended September 30, 2026
- Allocated and utilized for working capital: ₹52.10 lakh with nil deviation
Samsrita Labs approved its un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The auditor's report emphasized shareholder approvals for a proposed investment of up to ₹21.00 crore in CCPS of S Labs Hygiene Care Pvt Ltd, which is expected to be undertaken in Q3 FY27. Additionally, the company approved a material related-party transaction to sell goods worth up to ₹25.00 crore to S Labs Hygiene Care over the next year, compared to a company market cap of just ₹28 crore and negligible TTM revenue. The board also approved an unsecured loan of up to ₹1.00 crore at 9% interest from Non-Executive Director Ravi Kanth Naga Pattabhi Chopperla.
- Proposed CCPS investment of up to ₹21,00,00,000 in S Labs Hygiene Care Private Limited expected in Q3 FY 2026-27.
- Approval for material related-party transaction involving sale of goods up to ₹25,00,00,000 to S Labs Hygiene Care between 26 Oct 2026 and 25 Oct 2027.
- Approval to avail unsecured loan of up to ₹1,00,00,000 at 9% interest per annum from Non-Executive Director Ravi Kanth Naga Pattabhi Chopperla.
- Standalone cash and cash equivalents stood at ₹262.62 lakhs at the beginning of the period.
- Consolidated results factor in losses of ₹5,713.18 from Krisani Biosciences (32.91% stake) and ₹16,62,332.58 from Qrops Advisory Services (28.62% stake).
Samsrita Labs Limited has scheduled a Board of Directors meeting for November 11, 2026, to review and approve un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company operates at near-zero revenue (Rs 0.00 Cr in Q1 FY27 and TTM Rs 0 Cr) with persistent net losses (TTM net profit of Rs -8 Cr). The trading window for insiders has been closed since October 1, 2026, and will remain closed until 48 hours post-result declaration.
- Board meeting scheduled on Wednesday, November 11, 2026 at 03.30 P.M.
- Agenda includes consideration of un-audited standalone and consolidated results for the period ended September 30, 2026
- Trading window closed from October 1, 2026 until 48 hours post result declaration
Samsrita Labs has issued a notice for an Extraordinary General Meeting (EGM) scheduled on October 26, 2026, seeking shareholder approval for key related-party transactions. The resolutions include sale of goods up to ₹25 crore to S Labs Hygiene Care Pvt Ltd, which is massive compared to Samsrita's FY26 turnover of just ₹1.81 lakhs. Additionally, the company seeks approval to invest up to ₹1 crore in CCPS of S Labs Hygiene Care and borrow up to ₹1 crore as an unsecured loan at 9% p.a. from Director Ravikanth Chopperla for working capital.
- Proposed related-party sales limit of up to ₹25,00,00,000 to S Labs Hygiene Care Pvt Ltd from Oct 26, 2026 to Oct 25, 2027
- Subscription to Compulsorily Convertible Preference Shares (CCPS) of S Labs Hygiene Care up to ₹1,00,00,000
- Availing an unsecured loan up to ₹1,00,00,000 at 9.00% interest per annum from Non-Executive Director Ravikanth Chopperla
- EGM scheduled for October 26, 2026, with the e-voting cut-off date set as October 19, 2026
Samsrita Labs' board has approved major related-party transactions with newly incorporated S Labs Hygiene Care Private Limited, an entity 80% owned by its Non-Executive Director Ravikanth Naga Pattabhi Chopperla. The company plans to invest up to ₹1.00 crore in Compulsory Convertible Preference Shares (CCPS) and enter into sale transactions of up to ₹25.00 crore in the pet care segment. Additionally, the company approved availing an unsecured working capital loan of up to ₹1.00 crore from the same director. These transactions, which are substantial relative to Samsrita's ₹28 crore market cap and negligible TTM revenue, require shareholder approval at the EGM on October 26, 2026.
- Proposed investment of up to ₹1,00,00,000 in CCPS of S Labs Hygiene Care Private Limited
- Approval of related-party sale transactions of up to ₹25,00,00,000 with S Labs Hygiene Care
- Unsecured working capital loan of up to ₹1,00,00,000 from Non-Executive Director Ravikanth Chopperla
- Target entity S Labs was incorporated on 10.07.2026, with the director holding an 80% equity stake
- Extra-Ordinary General Meeting (EGM) scheduled for 26.10.2026 to seek shareholder approval
Samsrita Labs has submitted its quarterly statement confirming no deviation in the utilization of ₹3.39 crore raised via a preferential issue on July 18, 2025. The funds were earmarked for working capital (₹52.10 lakhs), new projects (₹132.46 lakhs), repayment of promoter loans (₹88.31 lakhs), and general corporate purposes (₹66.23 lakhs). As of June 30, 2026, the company reports that the actual utilization remains in line with the original objects. This transparency is notable given the company's current financial distress, including zero TTM revenue and negative net profit.
- Total funds raised via preferential issue on 18-07-2025 amounted to ₹339.10 lakhs.
- Allocation for investment into new projects or ventures stands at ₹132.46 lakhs.
- Repayment of unsecured loans to Promoter Director was allocated ₹88.31 lakhs.
- Reported deviation or variation for the quarter ended June 30, 2026, is Nil.
- Company market cap is small at ₹26 Cr, making the ₹3.39 Cr fundraise significant at ~13% of market cap.
Samsrita Labs continues to struggle with zero operational revenue for the quarter ended June 30, 2026. The standalone net loss widened to ₹31.47 lakhs, compared to a loss of ₹11.87 lakhs in the preceding quarter (March 2026). Total expenses nearly doubled sequentially to ₹31.47 lakhs, primarily driven by 'Other Expenses' of ₹21.55 lakhs. With a market cap of only ₹26 crore and a history of significant losses, the company's financial health remains extremely weak.
- Revenue from operations remained at ₹0.00 for the quarter ended June 30, 2026.
- Standalone net loss widened to ₹31.47 lakhs from ₹11.87 lakhs in the previous quarter.
- Total expenses increased by approximately 87% quarter-on-quarter to ₹31.47 lakhs.
- Employee benefit expenses rose to ₹9.80 lakhs from ₹7.83 lakhs in the preceding quarter.
- The company's paid-up equity share capital stands at ₹2,274.97 lakhs.
Samsrita Labs continues to report zero operational revenue for the quarter ended June 30, 2026, maintaining its pre-revenue status. On a consolidated basis, the net loss narrowed to Rs 18.87 Lakhs compared to a loss of Rs 48.16 Lakhs in the year-ago period, aided by a Rs 12.60 Lakhs profit share from associate companies. Standalone expenses increased slightly to Rs 31.47 Lakhs from Rs 27.66 Lakhs YoY, primarily due to employee benefits and administrative costs. The company's financial health remains strained with a negative TTM PAT of approximately Rs 8 Cr and a market cap of only Rs 27 Cr.
- Revenue from operations remained at Rs 0.00 for the quarter ended June 30, 2026.
- Consolidated net loss narrowed to Rs 18.87 Lakhs from Rs 48.16 Lakhs in the corresponding quarter of the previous year.
- Standalone total expenses rose to Rs 31.47 Lakhs, up from Rs 27.66 Lakhs YoY.
- Associate companies (Krisani Bio Sciences and Qrops Advisory) contributed a profit share of Rs 12.60 Lakhs.
- Paid-up equity share capital remains at Rs 2,274.97 Lakhs with a face value of Rs 10 per share.
Samsrita Labs has scheduled a board meeting for August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is in a precarious financial state, reporting a net loss of ₹8.16 Cr in FY26 on negligible revenue of just ₹0.02 Cr. Investors should note the sharp decline in promoter holding, which fell from 48.25% in June 2025 to 25.44% by March 2026. The upcoming results are critical to see if the company has initiated any actual business operations.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
- Company reported a net loss of ₹8.16 Cr for the full year FY26.
- Revenue for the most recent quarter (March 2026) was only ₹0.02 Cr.
- Promoter holding has significantly decreased to 25.44% from 48.25% a year prior.
- Market capitalization stands at a micro-cap level of ₹26 Cr.
Samsrita Labs Limited has released its Annual Report for FY 2025-26 and scheduled its 30th Annual General Meeting (AGM) for August 10, 2026. The company is seeking shareholder approval for the appointment of two new directors, including an Independent Director for a five-year term. Notably, the agenda includes a special resolution to alter the Object Clause of the Memorandum of Association, indicating a potential shift or expansion in business activities. The cut-off date for determining voting eligibility is August 3, 2026.
- 30th Annual General Meeting to be held on August 10, 2026, via video conferencing.
- Cut-off date for e-voting and AGM participation set for August 3, 2026.
- Proposed appointment of Mr. Satyanarayana Murthy Varanasi as an Independent Director for a 5-year term until July 2031.
- Special resolution proposed for the alteration of the Object Clause of the Memorandum of Association.
- Consolidated financial statements include the performance of two associate companies for FY 2025-26.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
